Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Financial aspects of cancer treatment reduces compliance

New data being released today by the Association of Oncology Social Work (AOSW) demonstrate the extraordinary financial hardships that often complicate or compromise a patient’s battle against cancer. Sixty-three percent of oncology social workers surveyed said that financial issues reduce patients’ compliance with their cancer treatment – even though that treatment is key to their recovery. Forty percent of patients reported depleting their savings, while almost 30% reported dealing with bill collectors.

3 Dec 2009

Medical research experts explore new strategies to speed up treatments for medical disorders

Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugural Partnering for Cures meeting.

3 Dec 2009

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.

3 Dec 2009

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Bristol-Myers Squibb Company today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

3 Dec 2009

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

3 Dec 2009

FDA grants Fast Track designation for AEterna Zentaris' perifosine

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma.

2 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana.

2 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

More than 14-million Americans, with chronic or life altering diseases and cancer, can’t afford the medication they need because of the high out-of-pocket costs associated with their insurance coverage. That’s why the Chronic Disease Fund, a nonprofit organization, provides financial help to seriously ill Americans so they can get the medications they need to live without the fear of debt.

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

51st ASH meeting to feature 16 abstracts of MMRC

The Multiple Myeloma Research Consortium (MMRC) announced today that data from 13 of its clinical trials and three from the Multiple Myeloma Research Foundation (MMRF) Genomics Initiative, which analyzes tissue samples from the MMRC tissue bank, have been selected for oral or poster presentations at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH) to be held in New Orleans from December 5-8, 2009.

24 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Winship-led team identifies a way to exploit cancer cells' taste for glucose

The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

23 Nov 2009

Interim data from Geron's ongoing imetelstat trial presented at the AACR-NCI-EORTC conference

Geron Corporation today announced the presentation of interim data from its ongoing trial of imetelstat (GRN163L), a telomerase inhibitor drug, in patients with refractory, advanced solid cancers at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

19 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

First-quarter fiscal 2010 results announced by Senesco Technologies

Senesco Technologies, Inc. today reported financial results for the three months ended September 30, 2009.

17 Nov 2009

Scientists solve 50-year-old thalidomide puzzle

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer..

17 Nov 2009

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Financial aspects of cancer treatment reduces compliance

Medical research experts explore new strategies to speed up treatments for medical disorders

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

FDA grants Fast Track designation for AEterna Zentaris' perifosine

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

51st ASH meeting to feature 16 abstracts of MMRC

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Winship-led team identifies a way to exploit cancer cells' taste for glucose

Interim data from Geron's ongoing imetelstat trial presented at the AACR-NCI-EORTC conference

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

First-quarter fiscal 2010 results announced by Senesco Technologies

Scientists solve 50-year-old thalidomide puzzle

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in